Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Current Deferred Revenue: 2016-2025

Historic Current Deferred Revenue for Wave Life Sciences (WVE) over the last 10 years, with Sep 2025 value amounting to $46.5 million.

  • Wave Life Sciences' Current Deferred Revenue fell 65.77% to $46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 million, marking a year-over-year decrease of 65.77%. This contributed to the annual value of $66.0 million for FY2024, which is 56.04% down from last year.
  • Per Wave Life Sciences' latest filing, its Current Deferred Revenue stood at $46.5 million for Q3 2025, which was down 9.80% from $51.6 million recorded in Q2 2025.
  • Wave Life Sciences' 5-year Current Deferred Revenue high stood at $150.1 million for Q4 2023, and its period low was $8.7 million during Q3 2021.
  • Over the past 3 years, Wave Life Sciences' median Current Deferred Revenue value was $107.0 million (recorded in 2023), while the average stood at $97.4 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first plummeted by 89.86% in 2021, then skyrocketed by 375.50% in 2023.
  • Wave Life Sciences' Current Deferred Revenue (Quarterly) stood at $37.1 million in 2021, then fell by 14.93% to $31.6 million in 2022, then surged by 375.50% to $150.1 million in 2023, then crashed by 56.04% to $66.0 million in 2024, then crashed by 65.77% to $46.5 million in 2025.
  • Its Current Deferred Revenue was $46.5 million in Q3 2025, compared to $51.6 million in Q2 2025 and $57.3 million in Q1 2025.